ArticleFrontiers in immunology2026
Clinical, immunological and metabolomic risk factors associated with fibromyalgia in a cohort of patients with idiopathic inflammatory myopathies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical, immunological, and metabolomic factors associated with fibromyalgia (FM) in patients with idiopathic inflammatory myopathies (IIM) who are in clinical remission or complete response. Methods: In this cross-sectional, 49 patients with IIM meeting remission and/or complete clinical response criteria were evaluated with the PROMIS Pain Interference Short Form 8a as an initial screening tool and patients with clinically significant pain interference subsequently underwent assessment with the 2016 ACR criteria. Clinical data, flow cytometry of peripheral blood mononuclear cells, multiplex cytokine assays, and untargeted metabolomic profiling by GC-MS were performed. Multivariate logistic regression was used to identify variables associated with FM. Results: The prevalence of FM in this IIM cohort was 40.8%. FM was associated with higher patient global assessment scores, increased muscle damage, current prednisone use, and elevated serum levels of IL-6 and MCP-1. Immunophenotyping revealed reduced numbers of non-classical monocytes, CD8 Conclusion: Patients with IIM in remission and/or complete clinical response can present with clinical significant FM, which is associated with immune dysregulation and metabolic alterations. These findings highlight the need for routine FM screening in IIM and support the use of patient-reported outcomes to distinguish between inflammatory and nociplastic symptoms in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.